DOCSLIB.ORG

Inhibition of Cytochrome P450 2C8-Mediated Drug Metabolism by the Flavonoid Diosmetin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inhibition of Cytochrome P450 2C8-Mediated Drug Metabolism by the Flavonoid Diosmetin Drug Metab. Pharmacokinet. 26 (6): 559­568 (2011). Copyright © 2011 by the Japanese Society for the Study of Xenobiotics (JSSX) Regular Article Inhibition of Cytochrome P450 2C8-mediated Drug Metabolism by the Flavonoid Diosmetin Luigi QUINTIERI1,PietroPALATINI1,StefanoMORO2 and Maura FLOREANI1,* 1Department of Pharmacology and Anaesthesiology, University of Padova, Italy 2Molecular Modeling Section (MMS), Department of Pharmaceutical Sciences, University of Padova, Italy Full text of this paper is available at http://www.jstage.jst.go.jp/browse/dmpk Summary: The aim of this study was to assess the effects of diosmetin and hesperetin, two flavonoids present in various medicinal products, on CYP2C8 activity of human liver microsomes using paclitaxel oxidation to 6¡-hydroxy-paclitaxel as a probe reaction. Diosmetin and hesperetin inhibited 6¡-hydroxy- paclitaxel production in a concentration-dependent manner, diosmetin being about 16-fold more potent than hesperetin (mean IC50 values 4.25 « 0.02 and 68.5 « 3.3 µM for diosmetin and hesperetin, respectively). Due to the low inhibitory potency of hesperetin, we characterized the mechanism of diosmetin-induced inhibition only. This flavonoid proved to be a reversible, dead-end, full inhibitor of CYP2C8, its mean inhibition constant (Ki)being3.13« 0.11 µM. Kinetic analysis showed that diosmetin caused mixed-type inhibition, since it significantly decreased the Vmax (maximum velocity) and increased the Km value (substrate concentration yielding 50% of Vmax) of the reaction. The results of kinetic analyses were consistent with those of molecular docking simulation, which showed that the putative binding site of diosmetin coincided with the CYP2C8 substrate binding site. The demonstration that diosmetin inhibits CYP2C8 at concentrations similar to those observed after in vivo administration (in the low micromolar range) is of potential clinical relevance, since it may cause pharmacokinetic interactions with co- administered drugs metabolized by this CYP. Keywords: CYP2C8 inhibition; diosmetin; paclitaxel; drug­drug interactions, molecular docking simulations present in pharmaceutical preparations. For example, Introduction diosmin, the 7-rutinoside ¤rhamnosyl-D-glucoside¥ of the Flavonoids are polyphenolic compounds ¤produced as flavone diosmetin ¤3$,5,7-trihydroxy-4-methoxyflavone¥, secondary plant metabolites¥ widely ingested with the diet alone or in association ¤9:1, w/w¥ with hesperidin, the by humans. Their beneficial effects against oxidative stress 7-rutinoside of the flavanone hesperetin ¤3$,5,7-trihydroxy- and related pathologies1®3¥ have been mainly ascribed to their 4-methoxyflavanone¥¤Fig. 1¥, is widely used for the antioxidant activity,4¥ although flavonoids appear to exert management of chronic venous insufficiency, venous ulcers more complex biological effects, including inhibition of and hemorrhoids.9¥ However, the safe use of herbs or tumor proliferation, modulation of several enzymes and medications containing flavonoids should take adequate interaction with different signal transduction pathways.5¥ account of their potential for interactions with co- Moreover, they seem to exhibit cancer-preventive proper- administered drugs, since various clinical studies have ties, possibly due to inhibition of cytochromes P450 ¤CYP¥ demonstrated that some flavonoids modify the oral 1A1, CYP1A2 and CYP1B1, the CYP forms principally disposition kinetics of numerous drugs.10®15¥ For example, involved in the metabolism of pro-carcinogens.6®8¥ For these Rajnarayana et al. showed that oral treatment of healthy reasons, the use of dietary supplements and/or herbal volunteers with diosmin increases significantly the bioavail- medications containing flavonoids has consistently increased ability of metronidazole,12¥ diclofenac14¥ and chlorzoxa- in recent years. In many countries, some flavonoids are also zone,15¥ and hypothesized that diosmin-induced inhibition Received; May 30, 2011, Accepted; July 14, 2011 J-STAGE Advance Published Date: July 26, 2011, doi:10.2133/dmpk.DMPK-11-RG-048 *To whom correspondence should be addressed: Prof. Maura FLOREANI, Department of Pharmacology and Anaesthesiology, University of Padova, Largo Meneghetti 2, 35131 Padova, Italy. Tel. +39 049 827 5088, Fax. +39 049 827 5093, E-mail: m.fl[email protected] This work was supported by grants from the University of Padova, Italy. The molecular modeling work coordinated by S. M. was carried out also with financial support from the Italian Ministry of Education, University and Research (MIUR), Rome, Italy. 559 560 Luigi QUINTIERI, et al. Fig. 1. Basic structures and numbering system of flavones, flavanones and flavonols The figure also shows the substitutions for diosmetin (3′,5,7-trihydroxy-4-methoxyflavone) and hesperetin (3′,5,7-trihydroxy-4-methoxy- flavanone), and for some flavonols which also inhibit CYP2C8.24) Moreover, the structure of diosmin and hesperidin, natural glycosides of diosmetin and hesperetin, respectively, are reported. of the CYP enzymes catalyzing the biotransformation of terize the mechanism of CYP2C8 inhibition caused by these drugs was responsible for the observed pharmacoki- diosmetin, we performed both enzyme kinetic studies and netic interactions. We have recently demonstrated that molecular docking simulations, since these two techniques diosmetin, the absorbable aglycone of diosmin,16¥ to which provide useful complementary information on the mecha- orally administered diosmin is converted by rhamnosidases nisms of drug-enzyme interactions. of Enterobacteriaceae,17¥ is a potent in vitro inhibitor of human ¥ ¥ Materials and Methods CYP3A4/518 and CYP2C9,19 the CYP forms responsible for the metabolism of metronidazole and diclofenac, Human liver microsomes ¤HLMs¥ and reagents: respectively,12,14¥ thereby confirming the hypothesis of Pooled mixed-gender HLMs ¤obtained from 25 female and Rajnarayana et al.12,14¥ 27 male donors¥ were provided by Xenotech LLC ¤Lenexa, Since CYP2C9 shares more than 80% amino acid KS, USA¥. The microsomal fractions were stored in aliquots sequence identity with CYP2C8,20¥ a CYP form expressed at %80ôC until use. at relatively high levels ¤6®7% of total CYP content¥ in Diosmetin and hesperetin, purchased from Chromadex human liver21¥ and which plays a major role in the ¤Irvine, CA, USA¥, were dissolved in N,N-dimethylform- 22¥ ¤ ¥ ¤ ¥ fl metabolism of several therapeutically important drugs, amide DMF /H2O 50:50, v/v . Solutions of the avonoid the main aim of the present study was to assess whether were prepared daily and kept in ice until use. The final diosmetin is also an effective inhibitor of human CYP2C8. solvent concentration in the incubation medium was 0.5%. Because in some pharmaceutical preparations the flavone Paclitaxel was a kind gift from Indena ¤Milan, Italy¥, diosmin is associated with the flavanone hesperidin, which is whereas its 6Æ-hydroxy metabolite ¤6Æ-OH paclitaxel¥ was also likely to be hydrolyzed by intestinal microflora to its purchased from SPI-Bio ¤Montigny le Bretonneux, France¥. aglycone hesperetin,17¥ a further aim of our study was to test Paclitaxel and 6Æ-OH paclitaxel were dissolved in aceto- ¤ ¥ ¤ ¥ the effect of hesperetin on CYP2C8 activity. Although this nitrile CH3CN /H2O 50:50, v/v .CH3CN was chosen as enzyme has been shown to be inhibited by some flavonols, the solvent for paclitaxel since, at the final concentration such as quercetin, morin and fisetin ¤see Fig. 1¥,23,24¥ to the used in our incubation mixtures ¤1%¥, it had been shown best of our knowledge, no data are available in the literature to produce a negligible effect on CYP2C8-mediated concerning the effects of flavones and/or flavanones on paclitaxel hydroxylation.27¥ NADPH and DMF were CYP2C8-catalyzed reactions. In this study, we used the purchased from Sigma-Aldrich Italy ¤Milan, Italy¥. Potassium ¤ ¥ antitumor agent paclitaxel as a probe substrate for CYP2C8 dihydrogen phosphate KH2PO4 ,CH3CN and methanol activity of human liver microsomes ¤HLMs¥ for two main ¤all of HPLC grade¥ were from Carlo Erba Reagenti reasons: ¤1¥ 6Æ-hydroxylation of paclitaxel is a validated ¤Milan, Italy¥. Ultrapure water was obtained by means of a marker reaction of CYP2C8 activity,22,23¥ since CYP2C8 is Pure-Lab Option Q ¤Elga Lab-Water, High Wycombe, UK¥ the only CYP form catalyzing this reaction in humans;25¥ ¤2¥ apparatus. a possible inhibitory effect of diosmetin and/or hesperetin on Determination of 6Æ-OH-paclitaxel formation this metabolic reaction would be of great clinical relevance, rate by HLMs: Incubation of paclitaxel with HLMs was since formation of the inactive metabolite 6Æ-hydroxy- carried out in conditions yielding linear reaction rates with paclitaxel ¤6Æ-OH-paclitaxel¥ accounts for more than 60% of respect to microsomal protein concentration and incubation paclitaxel metabolic disposition in humans.25,26¥ To charac- time at all paclitaxel concentrations used for our assays. Copyright © 2011 by the Japanese Society for the Study of Xenobiotics (JSSX) Inhibition of CYP2C8 by Diosmetin 561 HLMs ¤final protein concentration: 0.5 mg/ml¥ were n © 6¥ in the presence of heat-inactivated microsomes ¤final incubated in a mixture ¤total volume: 200 µl¥ containing concentration: 0.5 mg/ml¥ processed exactly as the samples ¤ ¥ 100 mM KH2PO4 pH 7.4 , 0.5 mM NADPH, and increas- obtained from kinetic experiments. The calibration curves ing concentrations ¤n © 9¥ of paclitaxel ¤from 3 to 40 µM¥. were linear in the above-reported concentration range Moreover, in some experiments the incubation medium ¤r2 ; 0.99¥,
Load more

Recommended publications
  • Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid
    Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 231 _____________________________ _____________________________ Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21 BY JOHAN BYLUND ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2000 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmaceutical Pharmacology presented at Uppsala University in 2000 ABSTRACT Bylund, J. 2000. Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid: Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from Faculty of Pharmacy 231 50 pp. Uppsala. ISBN 91-554-4784-8. Cytochrome P450 (P450 or CYP) is an enzyme system involved in the oxygenation of a wide range of endogenous compounds as well as foreign chemicals and drugs. This thesis describes investigations of P450-catalyzed oxygenation of prostaglandins, linoleic and arachidonic acids. The formation of bisallylic hydroxy metabolites of linoleic and arachidonic acids was studied with human recombinant P450s and with human liver microsomes. Several P450 enzymes catalyzed the formation of bisallylic hydroxy metabolites. Inhibition studies and stereochemical analysis of metabolites suggest that the enzyme CYP1A2 may contribute to the biosynthesis of bisallylic hydroxy fatty acid metabolites in adult human liver microsomes. 19R-Hydroxy-PGE and 20-hydroxy-PGE are major components of human and ovine semen, respectively. They are formed in the seminal vesicles, but the mechanism of their biosynthesis is unknown. Reverse transcription-polymerase chain reaction using degenerate primers for mammalian CYP4 family genes, revealed expression of two novel P450 genes in human and ovine seminal vesicles.
    [Show full text]
  • Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
    pharmaceutics Review Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice Malavika Deodhar 1, Sweilem B Al Rihani 1 , Meghan J. Arwood 1, Lucy Darakjian 1, Pamela Dow 1 , Jacques Turgeon 1,2 and Veronique Michaud 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA; [email protected] (M.D.); [email protected] (S.B.A.R.); [email protected] (M.J.A.); [email protected] (L.D.); [email protected] (P.D.); [email protected] (J.T.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +1-856-938-8697 Received: 5 August 2020; Accepted: 31 August 2020; Published: 4 September 2020 Abstract: In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity.
    [Show full text]
  • Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives
    pharmaceuticals Article Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives Subrata Deb * , Anthony Allen Reeves and Suki Lafortune Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, Miami, FL 33169, USA; [email protected] (A.A.R.); [email protected] (S.L.) * Correspondence: [email protected] or [email protected]; Tel.: +1-224-310-7870 or +1-305-760-7479 Received: 9 June 2020; Accepted: 20 July 2020; Published: 23 July 2020 Abstract: Vitamin D3 is an endogenous fat-soluble secosteroid, either biosynthesized in human skin or absorbed from diet and health supplements. Multiple hydroxylation reactions in several tissues including liver and small intestine produce different forms of vitamin D3. Low serum vitamin D levels is a global problem which may origin from differential absorption following supplementation. The objective of the present study was to estimate the physicochemical properties, metabolism, transport and pharmacokinetic behavior of vitamin D3 derivatives following oral ingestion. GastroPlus software, which is an in silico mechanistically-constructed simulation tool, was used to simulate the physicochemical and pharmacokinetic behavior for twelve vitamin D3 derivatives. The Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) Predictor and PKPlus modules were employed to derive the relevant parameters from the structural features of the compounds. The majority of the vitamin D3 derivatives are lipophilic (log P values > 5) with poor water solubility which are reflected in the poor predicted bioavailability. The fraction absorbed values for the vitamin D3 derivatives were low except for calcitroic acid, 1,23S,25-trihydroxy-24-oxo-vitamin D3, and (23S,25R)-1,25-dihydroxyvitamin D3-26,23-lactone each being greater than 90% fraction absorbed.
    [Show full text]
  • Time-Dependent Inhibition of CYP2C8 and CYP2C19 by Hedera Helix Extracts, a Traditional Respiratory Herbal Medicine
    molecules Article Time-dependent Inhibition of CYP2C8 and CYP2C19 by Hedera helix Extracts, A Traditional Respiratory Herbal Medicine Shaheed Ur Rehman 1, In Sook Kim 2, Min Sun Choi 2, Seung Hyun Kim 3, Yonghui Zhang 4 and Hye Hyun Yoo 2,* 1 Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad 22060, Pakistan; [email protected] 2 Institute of Pharmaceutical Science and Technology and College of Pharmacy, Hanyang University, Ansan, Gyeonggi-do 15588, Korea; [email protected] (I.S.K.); [email protected] (M.S.C.) 3 College of Pharmacy, Yonsei Institute of Pharmaceutical Science, Yonsei University, Incheon 21983, Korea; [email protected] 4 School of Pharmacy, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China; [email protected] * Correspondence: [email protected]; Tel.: +82-31-400-5804; Fax: +82-31-400-5958 Received: 1 June 2017; Accepted: 20 July 2017; Published: 24 July 2017 Abstract: The extract of Hedera helix L. (Araliaceae), a well-known folk medicine, has been popularly used to treat respiratory problems, worldwide. It is very likely that this herbal extract is taken in combination with conventional drugs. The present study aimed to evaluate the effects of H. helix extract on cytochrome P450 (CYP) enzyme-mediated metabolism to predict the potential for herb–drug interactions. A cocktail probe assay was used to measure the inhibitory effect of CYP. H. helix extracts were incubated with pooled human liver microsomes or CYP isozymes with CYP-specific substrates, and the formation of specific metabolites was investigated to measure the inhibitory effects.
    [Show full text]
  • Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese Population
    Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Halling, Jónrit, Maria S. Petersen, Per Damkier, Flemming Nielsen, Philippe Grandjean, Pál Weihe, Stefan Lundgren, Mia Sandberg Lundblad, and Kim Brøsen. 2005. “Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese Population.” European Journal of Clinical Pharmacology 61 (7) (July 16): 491–497. doi:10.1007/s00228-005-0938-1. Published Version doi:10.1007/s00228-005-0938-1 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34786606 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA POLYMORPHISM OF CYP2D6, CYP2C19, CYP2C9 AND CYP2C8 IN THE FAROESE POPULATION Jónrit Halling1, Maria S. Petersen2, Per Damkier3, Flemming Nielsen1,2 , Philippe Grandjean2, Pál Weihe4, Stefan Lundgren5, Mia Sandberg Lundblad5 and Kim Brøsen1 1 Institute of Public Health, Clinical Pharmacology, University of Southern Denmark, Winslovparken 19, 5000 Odense C, Denmark. 2 Institute of Public Health, Enviromental Medicine, University of Southern Denmark, Winslovparken 17, 5000 Odense C, Denmark. 3Department KKA, Clinical Pharmacology, Odense University Hospital, Odense, Denmark 4 The Faroese Hospital System, Department of Occupational
    [Show full text]
  • Recent Advances in P450 Research
    The Pharmacogenomics Journal (2001) 1, 178–186 2001 Nature Publishing Group All rights reserved 1470-269X/01 $15.00 www.nature.com/tpj REVIEW Recent advances in P450 research JL Raucy1,2 ABSTRACT SW Allen1,2 P450 enzymes comprise a superfamily of heme-containing proteins that cata- lyze oxidative metabolism of structurally diverse chemicals. Over the past few 1La Jolla Institute for Molecular Medicine, San years, there has been significant progress in P450 research on many fronts Diego, CA 92121, USA; 2Puracyp Inc, San and the information gained is currently being applied to both drug develop- Diego, CA 92121, USA ment and clinical practice. Recently, a major accomplishment occurred when the structure of a mammalian P450 was determined by crystallography. Correspondence: Results from these studies will have a major impact on understanding struc- JL Raucy,La Jolla Institute for Molecular Medicine,4570 Executive Dr,Suite 208, ture-activity relationships of P450 enzymes and promote prediction of drug San Diego,CA 92121,USA interactions. In addition, new technologies have facilitated the identification Tel: +1 858 587 8788 ext 116 of several new P450 alleles. This information will profoundly affect our under- Fax: +1 858 587 6742 E-mail: jraucyȰljimm.org standing of the causes attributed to interindividual variations in drug responses and link these differences to efficacy or toxicity of many thera- peutic agents. Finally, the recent accomplishments towards constructing P450 null animals have afforded determination of the role of these enzymes in toxicity. Moreover, advances have been made towards the construction of humanized transgenic animals and plants. Overall, the outcome of recent developments in the P450 arena will be safer and more efficient drug ther- apies.
    [Show full text]
  • Polymorphisms of CYP2C8 Alter First-Electron Transfer Kinetics and Increase Catalytic Uncoupling
    International Journal of Molecular Sciences Article Polymorphisms of CYP2C8 Alter First-Electron Transfer Kinetics and Increase Catalytic Uncoupling William R. Arnold 1 , Susan Zelasko 1, Daryl D. Meling 1, Kimberly Sam 1 and Aditi Das 1,2,3,4,* 1 Department of Biochemistry, University of Illinois Urbana-Champaign, 3813 Veterinary Medicine Basic Sciences Building, 2001 South Lincoln Avenue, Urbana, IL 61802, USA; [email protected] (W.R.A.); [email protected] (S.Z.); [email protected] (D.D.M.); [email protected] (K.S.) 2 Department of Comparative Biosciences, University of Illinois Urbana-Champaign, 3813 Veterinary Medicine Basic Sciences Building, 2001 South Lincoln Avenue, Urbana, IL 61802, USA 3 Department of Bioengineering, University of Illinois Urbana-Champaign, Beckman Institute for Advanced Science and Technology, 3813 Veterinary Medicine Basic Sciences Building, 2001 South Lincoln Avenue, Urbana, IL 61802, USA 4 Division of Nutritional Sciences, University of Illinois Urbana-Champaign, 3813 Veterinary Medicine Basic Sciences Building, 2001 South Lincoln Avenue, Urbana, IL 61802, USA * Correspondence: [email protected]; Tel.: +1217-244-0630 Received: 30 August 2019; Accepted: 13 September 2019; Published: 18 September 2019 Abstract: Cytochrome P450 2C8 (CYP2C8) epoxygenase is responsible for the metabolism of over 60 clinically relevant drugs, notably the anticancer drug Taxol (paclitaxel, PAC). Specifically, there are naturally occurring polymorphisms, CYP2C8*2 and CYP2C8*3, that display altered PAC hydroxylation rates despite these mutations not being located in the active site. Herein, we demonstrate that these polymorphisms result in a greater uncoupling of PAC metabolism by increasing the amount of hydrogen peroxide formed per PAC turnover.
    [Show full text]
  • Chapter I Introduction
    LI, TIANGANG, Ph.D., May, 2006 BIOMEDICAL SCIENCES PREGNANE X RECEPTOR REGULATION OF BILE ACID METABOLISM AND CHOLESTEROL HOMEOSTASIS (189 PP.) Director of Dissertation: John Y. L. Chiang, Ph.D The nuclear receptor pregnane X receptor (PXR) is activated by bile acids, steroids and drugs and regulates a network of genes in lipid and drug mechanisms. The goal of this study is to investigate the role of PXR in the coordinate regulation of bile acid synthetic and detoxification genes and its implications in cholestatic liver diseases and treatments. Cholesterol 7α hydroxylase (CYP7A1) catalyzes the rate-limiting step in the classic bile acids synthetic pathway and plays a key role in controlling bile acids homeostasis. Quantitative real-time PCR (Q-PCR) showed human PXR agonist rifampicin inhibited CYP7A1 mRNA expression in primary human hepatocytes. Mammalian two-hybrid assays, co-immunoprecipitation (co-IP) assays and chromatin immunoprecipitation (ChIP) assay revealed that ligand-activated PXR strongly interacted with HNF4α, the key activator of human CYP7A1, and blocked HNF4α interaction with co-activator PGC-1α, thus resulted in inhibition of CYP7A1. CYP3A4 is the most abundant cytochrome P450 monooxygenase expressed in human liver and intestine. Bile acids and drugs-activated PXR induces CYP3A4, which converts toxic bile acids to non-toxic metabolites for excretion. Studies using Q-PCR, reporter assays, GST pull-down assays and ChIP assays revealed that PXR strongly induced CYP3A4 gene transcription by interacting with HNF4α, SRC-1 and PGC-1α. SHP, a negative nuclear receptor, reduced PXR recruitment of HNF4α and SRC-1 to the CYP3A4 chromatin and inhibited CYP3A4.
    [Show full text]
  • Animal Models to Study Bile Acid Metabolism T ⁎ Jianing Li, Paul A
    BBA - Molecular Basis of Disease 1865 (2019) 895–911 Contents lists available at ScienceDirect BBA - Molecular Basis of Disease journal homepage: www.elsevier.com/locate/bbadis ☆ Animal models to study bile acid metabolism T ⁎ Jianing Li, Paul A. Dawson Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Emory University, Atlanta, GA 30322, United States ARTICLE INFO ABSTRACT Keywords: The use of animal models, particularly genetically modified mice, continues to play a critical role in studying the Liver relationship between bile acid metabolism and human liver disease. Over the past 20 years, these studies have Intestine been instrumental in elucidating the major pathways responsible for bile acid biosynthesis and enterohepatic Enterohepatic circulation cycling, and the molecular mechanisms regulating those pathways. This work also revealed bile acid differences Mouse model between species, particularly in the composition, physicochemical properties, and signaling potential of the bile Enzyme acid pool. These species differences may limit the ability to translate findings regarding bile acid-related disease Transporter processes from mice to humans. In this review, we focus primarily on mouse models and also briefly discuss dietary or surgical models commonly used to study the basic mechanisms underlying bile acid metabolism. Important phenotypic species differences in bile acid metabolism between mice and humans are highlighted. 1. Introduction characteristics such as small size, short gestation period and life span, which facilitated large-scale laboratory breeding and housing, the Interest in bile acids can be traced back almost three millennia to availability of inbred and specialized strains as genome sequencing the widespread use of animal biles in traditional Chinese medicine [1].
    [Show full text]
  • Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions
    1521-0081/68/1/168–241$25.00 http://dx.doi.org/10.1124/pr.115.011411 PHARMACOLOGICAL REVIEWS Pharmacol Rev 68:168–241, January 2016 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: MARKKU KOULU Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions Janne T. Backman, Anne M. Filppula, Mikko Niemi, and Pertti J. Neuvonen Department of Clinical Pharmacology, University of Helsinki (J.T.B., A.M.F., M.N., P.J.N.), and Helsinki University Hospital, Helsinki, Finland (J.T.B., M.N., P.J.N.) Abstract ...................................................................................169 I. Introduction . ..............................................................................169 II. Basic Characteristics of Cytochrome P450 2C8 . ..........................................170 A. Genomic Organization and Transcriptional Regulation . ...............................170 B. Protein Structure ......................................................................171 C. Expression .............................................................................172 III. Substrates of Cytochrome P450 2C8. ......................................................173 A. Drugs..................................................................................173 1. Anticancer Agents...................................................................173 Downloaded from 2. Antidiabetic Agents. ................................................................183 3. Antimalarial Agents.................................................................183
    [Show full text]
  • Biodiversity of P-450 Monooxygenase: Cross-Talk
    Cytochrome P450: Oxygen activation and biodiversty 1 Biodiversity of P-450 monooxygenase: Cross-talk between chemistry and biology Heme Fe(II)-CO complex 450 nm, different from those of hemoglobin and other heme proteins 410-420 nm. Cytochrome Pigment of 450 nm Cytochrome P450 CYP3A4…. 2 High Energy: Ultraviolet (UV) Low Energy: Infrared (IR) Soret band 420 nm or g-band Mb Fe(II) ---------- Mb Fe(II) + CO - - - - - - - Visible region Visible bands Q bands a-band, b-band b a 3 H2O/OH- O2 CO Fe(III) Fe(II) Fe(II) Fe(II) Soret band at 420 nm His His His His metHb deoxy Hb Oxy Hb Carbon monoxy Hb metMb deoxy Mb Oxy Mb Carbon monoxy Mb H2O/Substrate O2-Substrate CO Substrate Soret band at 450 nm Fe(III) Fe(II) Fe(II) Fe(II) Cytochrome P450 Cys Cys Cys Cys Active form 4 Monooxygenase Reactions by Cytochromes P450 (CYP) + + RH + O2 + NADPH + H → ROH + H2O + NADP RH: Hydrophobic (lipophilic) compounds, organic compounds, insoluble in water ROH: Less hydrophobic and slightly soluble in water. Drug metabolism in liver ROH + GST → R-GS GST: glutathione S-transferase ROH + UGT → R-UG UGT: glucuronosyltransferaseGlucuronic acid Insoluble compounds are converted into highly hydrophilic (water soluble) compounds. 5 Drug metabolism at liver: Sleeping pill, pain killer (Narcotic), carcinogen etc. Synthesis of steroid hormones (steroidgenesis) at adrenal cortex, brain, kidney, intestine, lung, Animal (Mammalian, Fish, Bird, Insect), Plants, Fungi, Bacteria 6 NSAID: non-steroid anti-inflammatory drug 7 8 9 10 11 Cytochrome P450: Cysteine-S binding to Fe(II) heme is important for activation of O2.
    [Show full text]
  • RNA Editing Enzymes Modulate the Expression of Hepatic CYP2B6, CYP2C8, and Other Cytochrome P450 Isoforms
    1521-009X/47/6/639–647$35.00 https://doi.org/10.1124/dmd.119.086702 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 47:639–647, June 2019 Copyright ª 2019 by The American Society for Pharmacology and Experimental Therapeutics RNA Editing Enzymes Modulate the Expression of Hepatic CYP2B6, CYP2C8, and Other Cytochrome P450 Isoforms Kaori Nozaki, Masataka Nakano, Chika Iwakami, Tatsuki Fukami, and Miki Nakajima Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences (K.N., Ma.N., C.I., T.F., Mi.N.), and WPI Nano Life Science Institute (Ma.N., T.F., Mi.N.), Kanazawa University, Kakuma-machi, Kanazawa, Japan Received February 10, 2019; accepted April 8, 2019 ABSTRACT A-to-I RNA editing, the most frequent type of RNA editing in expression by the knockdown of ADARs. We found that the de- mammals, is catalyzed by adenosine deaminase acting on RNA creased expression of the hepatocyte nuclear factor 4a (HNF4a) (ADAR) enzymes. Recently, we found that there is a large interindi- protein by the knockdown of ADARs was one of the reasons for the Downloaded from vidual variation in the expression of ADAR1 protein in the human decreased transactivity of CYP2C8. The mRNA levels of other P450 livers. In this study, we investigated the possibility that A-to-I RNA isoforms, such as CYP2A6, 2C9, 2C19, 2D6, and 2E1, which are editing may modulate the expression of cytochrome P450 (P450), known to be regulated by HNF4a, were also decreased by ADAR1 or causing interindividual variations in drug metabolism potencies. We ADAR2 knockdown. Exceptionally, the CYP3A4 mRNA level was found that knockdown of ADAR1 or ADAR2 in HepaRG cells resulted significantly increased by ADAR1 knockdown, suggesting the in the decreased expression of CYP2B6 and CYP2C8 mRNA and possibility that the change could be due to the change in the dmd.aspetjournals.org protein.
    [Show full text]